Part II: Hodgkin's lymphoma???diagnosis and treatment, The Lancet Oncology, vol.5, issue.1, pp.19-26, 2004. ,
DOI : 10.1016/S1470-2045(03)01320-2
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, issue.19, pp.5019-5051, 2011. ,
DOI : 10.1182/blood-2011-01-293050
Cancer statistics, CA Cancer J Clin. 2015 Feb, vol.65, issue.1, pp.5-29, 2015. ,
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, issue.suppl 3, pp.70-75, 2014. ,
DOI : 10.1093/annonc/mdu181
Hodgkin Lymphoma Available from, Hematologic Malignancies), pp.978-981, 2015. ,
A Prognostic Score for Advanced Hodgkin's Disease, New England Journal of Medicine, vol.339, issue.21, pp.1506-1520, 1998. ,
DOI : 10.1056/NEJM199811193392104
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting., Journal of Clinical Oncology, vol.7, issue.11, pp.1630-1636, 1989. ,
DOI : 10.1200/JCO.1989.7.11.1630
Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin???s Disease: Report of an Intergroup Trial, Journal of Clinical Oncology, vol.21, issue.4, pp.607-621, 2003. ,
DOI : 10.1200/JCO.2003.12.086
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease, New England Journal of Medicine, vol.348, issue.24, pp.2386-95, 2003. ,
DOI : 10.1056/NEJMoa022473
Report on the 4th International Workshop on Positron Emission Tomography in Lymphoma, Leuk Lymphoma, vol.55, issue.1, pp.3-531, 2012. ,
Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma, Annals of Oncology, vol.16, issue.7, pp.1160-1168, 2005. ,
DOI : 10.1093/annonc/mdi200
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, vol.107, issue.1, pp.52-61, 2006. ,
DOI : 10.1182/blood-2005-06-2252
Treatment of Hodgkin lymphoma: the past, present, and future, Nature Clinical Practice Oncology, vol.11, issue.9, pp.543-56, 2008. ,
DOI : 10.1038/ncponc1186
The new therapeutical scenario of Hodgkin lymphoma, Annals of Oncology, vol.26, issue.10, pp.2026-2059, 2015. ,
DOI : 10.1093/annonc/mdv256
Treatment of Hodgkin Lymphoma: A 50-Year Perspective, Journal of Clinical Oncology, vol.32, issue.3, pp.163-171, 2014. ,
DOI : 10.1200/JCO.2013.53.1194
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA, Mediterranean Journal of Hematology and Infectious Diseases, vol.6, issue.1, p.2014053, 2014. ,
DOI : 10.4084/mjhid.2014.053
Pathogenesis of Classical and Lymphocyte-Predominant Hodgkin Lymphoma, Annual Review of Pathology: Mechanisms of Disease, vol.4, issue.1, pp.151-74, 2009. ,
DOI : 10.1146/annurev.pathol.4.110807.092209
Mutations in the genes coding for the NF-??B regulating factors I??B?? and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma, Haematologica, vol.95, issue.1, pp.153-160, 2010. ,
DOI : 10.3324/haematol.2009.010157
Molecular Karyotypes of Hodgkin and Reed-Sternberg Cells at Disease Onset Reveal Distinct Copy Number Alterations in Chemosensitive versus Refractory Hodgkin Lymphoma, Clinical Cancer Research, vol.17, issue.10, pp.3443-54, 2011. ,
DOI : 10.1158/1078-0432.CCR-10-1071
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood, Feb, vol.12125, issue.7, pp.1061-72, 2015. ,
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood, Feb, vol.1599, issue.4, pp.1474-1481, 2002. ,
Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2, Blood, vol.99, issue.4, 2002. ,
DOI : 10.1182/blood.V99.4.1381
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study, Clinical Cancer Research, vol.22, issue.12 ,
DOI : 10.1158/1078-0432.CCR-15-2305
URL : https://hal.archives-ouvertes.fr/hal-01442496
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes, Chromosomes and Cancer, vol.110, issue.3, 2015. ,
DOI : 10.1002/gcc.22328
URL : https://hal.archives-ouvertes.fr/hal-01237083
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma, Blood, vol.114, issue.6, pp.1236-1278, 2009. ,
DOI : 10.1182/blood-2009-03-209759
URL : https://hal.archives-ouvertes.fr/inserm-00411059
The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood, pp.2659-69, 2011. ,
CRM1 is an export receptor for leucine-rich nuclear export signals. Cell, pp.1051-60, 1997. ,
CRM1 is responsible for intracellular transport mediated by the nuclear export signal, Nature, vol.390, issue.6657, pp.308-319, 1997. ,
Mechanisms of Receptor-Mediated Nuclear Import and Nuclear Export. Traffic, pp.187-98, 2005. ,
The CRM1 nuclear export protein in normal development and disease, Int J Biochem Mol Biol, vol.3, issue.2, pp.137-51, 2012. ,
Allosteric control of the exportin CRM1 unraveled by crystal structure analysis, FEBS Journal, vol.24, issue.18, pp.4179-94, 2014. ,
DOI : 10.1111/febs.12842
SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients, Leukemia, vol.98, issue.1, pp.108-125, 2014. ,
DOI : 10.1038/leu.2013.263
Genomic and molecular characterization of esophageal squamous cell carcinoma, Nature Genetics, vol.31, issue.5, pp.467-73, 2014. ,
DOI : 10.1093/nar/gkt439
Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma, Nature Genetics, vol.362, issue.4, pp.329-364 ,
DOI : 10.1038/ng.2900
KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia, British Journal of Haematology, vol.21, issue.1, pp.117-144 ,
DOI : 10.1111/bjh.12231
Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood, pp.4621-4655, 2012. ,
The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL) [Abstract 396, 56th ASH Annual Meeting, 2014. ,
Liquid Biopsies: Genotyping Circulating Tumor DNA, Journal of Clinical Oncology, vol.32, issue.6, pp.579-86, 2014. ,
DOI : 10.1200/JCO.2012.45.2011
Somatic mutations of cell-free circulating DNA detected by Next Generation Sequencing reflect the genetic changes in both Germinal Center B-Cell like and Activated B-Cell like Diffuse Large B- Cell Lymphoma tumors at the time of diagnosis, Haematologica, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01132460
Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study, The Lancet Haematology, vol.2, issue.2, pp.55-65, 2015. ,
DOI : 10.1016/S2352-3026(14)00039-8
Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach, British Journal of Haematology, vol.14, issue.5, pp.689-93 ,
DOI : 10.1111/bjh.13349
Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.122, issue.9, 2016. ,
DOI : 10.1182/blood.V98.9.2762
Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: Implications for targeted EZH2 inhibitor therapy?, Oncotarget, vol.6, issue.18, 2015. ,
DOI : 10.18632/oncotarget.3154
Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.579-86, 2007. ,
DOI : 10.1200/JCO.2006.09.2403
Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient, Blood, vol.87, issue.8, pp.3429-3465, 1996. ,
Two neoplastic cell lines with unique features derived from Hodgkin's disease, International Journal of Cancer, vol.41, issue.6, pp.723-754, 1980. ,
DOI : 10.1002/ijc.2910260605
Phenotypic and genotypic analysis of Hodgkin's disease derived cell lines: histopathological and clinical implications, Cancer Surv, vol.4, issue.2, pp.399-419, 1985. ,
Cellular protein profiles of the Hodgkin's disease cell lines L428, KM-H2 and HDLM-2: A comparative study, Leukemia Research, vol.16, issue.3, pp.253-63, 1992. ,
DOI : 10.1016/0145-2126(92)90063-D
Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice, Annals of Oncology, vol.5, issue.suppl 1, pp.121-127, 1994. ,
DOI : 10.1093/annonc/5.suppl_1.S121
A new cell line derived from a primary refractory classical Hodgkin lymphoma]. Pathol, pp.317-325, 2008. ,
The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing, Leukemia, vol.28, issue.11, pp.2248-51, 2014. ,
DOI : 10.1038/ng.2469
Mediastinal Gray Zone Lymphoma, The American Journal of Surgical Pathology, vol.29, issue.11, pp.1411-1432, 2005. ,
DOI : 10.1097/01.pas.0000180856.74572.73
URL : https://hal.archives-ouvertes.fr/hal-01471621
Cryptic XPO1-MLLT10 translocation is associated with HOXA locus deregulation in T-ALL. Blood, pp.3023-3028, 2014. ,
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. Blood, pp.2110-2117, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01263113
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.25, issue.7354, pp.101-106, 2011. ,
DOI : 10.1038/nature10113
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes, Chromosomes and Cancer, vol.110, issue.3, 2015. ,
DOI : 10.1002/gcc.22328
URL : https://hal.archives-ouvertes.fr/hal-01237083
Identification of a Nuclear Export Sequence in the MHC CIITA, The Journal of Immunology, vol.194, issue.12, pp.6102-6113, 2015. ,
DOI : 10.4049/jimmunol.1402026
FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood, Apr, vol.12119, issue.15, pp.3503-3514, 2012. ,
Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo, Clinical Cancer Research, vol.20, issue.10, pp.2674-83, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-3007
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition, 2008. ,
PCR-mismatch analysis of p53 gene mutation in Hodgkin's disease, The Journal of Pathology, vol.56, issue.2, pp.189-94, 1995. ,
DOI : 10.1002/path.1711750206
p53 mutations in Hodgkin's disease. Lab Investig J Tech Methods Pathol, pp.519-546, 1996. ,
TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus, International Journal of Cancer, vol.16, issue.1, pp.60-66, 2001. ,
DOI : 10.1002/ijc.1438
Recurrent somatic loss of TNFRSF14 in classical Hodgkin lymphoma, Genes Chromosomes Cancer, 2009. ,
Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation, Oncogene, vol.28, issue.18, pp.2679-84, 2006. ,
DOI : 10.1038/sj.onc.1209151
STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL), Oncotarget, vol.4, issue.7, pp.1093-102, 2013. ,
DOI : 10.18632/oncotarget.1149
(A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma, The Journal of Experimental Medicine, vol.161, issue.5, pp.981-990, 2009. ,
DOI : 10.1159/000112062
Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma, Cancer Genetics and Cytogenetics, vol.197, issue.2, pp.152-159, 2010. ,
DOI : 10.1016/j.cancergencyto.2009.11.005
Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells, The Journal of Pathology, vol.376, issue.3, pp.413-433, 2003. ,
DOI : 10.1002/path.1454
Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma, Oncotarget, vol.6, issue.30, pp.29097-110, 2015. ,
Low Frequency of FAS Mutations in Reed-Sternberg Cells of Hodgkin's Lymphoma, The American Journal of Pathology, vol.162, issue.1, pp.29-35, 2003. ,
DOI : 10.1016/S0002-9440(10)63795-9
Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial, Blood, vol.121, issue.18, pp.3547-53, 2013. ,
DOI : 10.1182/blood-2012-09-454694
Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma, Clinical Cancer Research, vol.19, issue.3, pp.731-773 ,
DOI : 10.1158/1078-0432.CCR-12-2693
The Clinical Utilization of Circulating Cell Free DNA (CCFDNA) in Blood of Cancer Patients, International Journal of Molecular Sciences, vol.14, issue.9, pp.18925-58, 2013. ,
DOI : 10.3390/ijms140918925
Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients, International Journal of Cancer, vol.945, issue.3, pp.361-70, 2003. ,
DOI : 10.1002/ijc.11079
Quantification of plasma DNA as a screening tool for lung cancer, Chin Med J (Engl), vol.117, issue.10, pp.1485-1493, 2004. ,
Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease, British Journal of Cancer, vol.66, issue.3, pp.476-83, 2015. ,
DOI : 10.1038/bjc.2015.225
Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: a LYSA Study. 57th ASH, oral abstract #129, Blood, issue.23, p.126, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01300803
Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials, Blood, vol.73, issue.1, pp.1964-198747, 1989. ,